AI-Powered Drug Design Program

Deargen streamlines the initial R&D stage of new drug development with A.I. Each of Deargen's programs focuses on diseases with high medical demands, such as anticancer drugs, cardiovascular and metabolic diseases, neurological diseases, and immune diseases.

Oncology

CVRM

Neurology

Immunology

4D Program

The 4D (Deargen-Driven Drug Development) program is a new drug development pipeline led by Deargen from the discovery of Hit substances. Using A.I, we develop optimal new drug candidates through the iterative process of prediction, synthesis, validation, and re-learning.

Target ID
Hit Discovery
Lead Optimization
Preclinical

DG-ONCO-T1

DG-ONCO-T2

DG-ONCO-T3

DG-ONCO-T4

DG-HF-T1

DG-HL-T1

DG-ALS-T1

Co-Developed Program

Deargen is developing new drugs through various cooperation with domestic and overseas drug developers.

Target ID
Hit Discovery
Lead Optimization
Preclinical

NASH - Target1

NASH - Target2

NASH - Target3

IPF - Target1

IPF - Target2

IPF - Target3

IPF - Target4

Oncology

Immunology

Hearing Loss

ALZHEIMER’s - Target1

ALZHEIMER’s - Target2

ALZHEIMER’s - Target3

ALZHEIMER’s - Target4

ALZHEIMER’s - Target4

oncology

oncology

Service Agreement

oncology

Service Agreement